Literature DB >> 15332431

Progression of HIV to AIDS: a protective role for HLA-B27?

Debby den Uyl1, Irene E van der Horst-Bruinsma, Michiel van Agtmael.   

Abstract

HLA-B27 is known for its strong association with inflammatory spondyloarthropathies (SpA), a group of rheumatic diseases. Apart from playing its role in the onset of these inflammatory diseases, HLA-827 is so ubiquitous in the world that the carrying of this gene must have also have an advantage. There are some indications that a beneficial effect can be found as a less severe course of viral infections among B27-carriers. The literature on this subject was reviewed and revealed a favorable course of infection with influenza virus, herpes simplex type 2 virus, Epstein-Barr virus and, even more interesting, a protective effect of HLA-B27 in the progression of HIV infections. The course of HIV infection differs among individuals and is thought to be partly related to host-factor variability, reflecting broad genetic heterogeneity. The polymorphic human leukocyte antigens (HLA) are herein analyzed intensively with respect to this relationship. Cytotoxic T lymphocyte (CTL) responses, activated by HLA antigen presentation, are implicated in the control of HIV replication. An immunological explanation for the protective role for HLA B27 in HIV disease is that B27+ patients have a specific and strong CTL response against the p24 epitope, a conservative HIV protein that does not easily mutate. Some HLA genes seen in long-term non-progressors (LTNP) (>10 years disease free) are associated with a favorable prognosis. One of the alleles found predominantly in LTNPs is HLA-B27. More genetic factors seem to influence disease progression in HIV infections. Therefore, it would be interesting to further explore the influence of the genetic make up of these HIV-infected individuals. Knowledge of the immunogenetic profile might give clues for the individual course of the HIV infection, may influence the development of drug-resistant viruses and will possibly lead to a tailored therapeutic strategy in HIV-infected persons.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15332431

Source DB:  PubMed          Journal:  AIDS Rev        ISSN: 1139-6121            Impact factor:   2.500


  22 in total

1.  HIV controllers with HLA-DRB1*13 and HLA-DQB1*06 alleles have strong, polyfunctional mucosal CD4+ T-cell responses.

Authors:  April L Ferre; Peter W Hunt; Delandy H McConnell; Megan M Morris; Juan C Garcia; Richard B Pollard; Hal F Yee; Jeffrey N Martin; Steven G Deeks; Barbara L Shacklett
Journal:  J Virol       Date:  2010-08-18       Impact factor: 5.103

2.  Immunodominant HIV-specific CD8+ T-cell responses are common to blood and gastrointestinal mucosa, and Gag-specific responses dominate in rectal mucosa of HIV controllers.

Authors:  April L Ferre; Donna Lemongello; Peter W Hunt; Megan M Morris; Juan Carlos Garcia; Richard B Pollard; Hal F Yee; Jeffrey N Martin; Steven G Deeks; Barbara L Shacklett
Journal:  J Virol       Date:  2010-07-28       Impact factor: 5.103

3.  Nef alleles from human immunodeficiency virus type 1-infected long-term-nonprogressor hemophiliacs with or without late disease progression are defective in enhancing virus replication and CD4 down-regulation.

Authors:  Andrea Crotti; Francesca Neri; Davide Corti; Silvia Ghezzi; Silvia Heltai; Andreas Baur; Guido Poli; Elena Santagostino; Elisa Vicenzi
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

4.  Impact of protective killer inhibitory receptor/human leukocyte antigen genotypes on natural killer cell and T-cell function in HIV-1-infected controllers.

Authors:  Costin Tomescu; Fuh-Mei Duh; Rebecca Hoh; Anne Viviani; Kara Harvill; Maureen P Martin; Mary Carrington; Steven G Deeks; Luis J Montaner
Journal:  AIDS       Date:  2012-09-24       Impact factor: 4.177

5.  Mosaic HIV-1 Gag antigens can be processed and presented to human HIV-specific CD8+ T cells.

Authors:  Zaza M Ndhlovu; Alicja Piechocka-Trocha; Seanna Vine; Ashley McMullen; Kegakilwe C Koofhethile; Phillip J R Goulder; Thumbi Ndung'u; Dan H Barouch; Bruce D Walker
Journal:  J Immunol       Date:  2011-05-16       Impact factor: 5.422

Review 6.  Role of Human Leukocyte Antigens (HLA) in Autoimmune Diseases.

Authors:  Gergely Bodis; Victoria Toth; Andreas Schwarting
Journal:  Rheumatol Ther       Date:  2018-03-07

7.  Fine-mapping of HLA associations with chronic lymphocytic leukemia in US populations.

Authors:  Loren Gragert; Stephanie Fingerson; Mark Albrecht; Martin Maiers; Matt Kalaycio; Brian T Hill
Journal:  Blood       Date:  2014-09-17       Impact factor: 22.113

8.  The identification of unique serum proteins of HIV-1 latently infected long-term non-progressor patients.

Authors:  Rachel Van Duyne; Irene Guendel; Kylene Kehn-Hall; Rebecca Easley; Zachary Klase; Chenglong Liu; Mary Young; Fatah Kashanchi
Journal:  AIDS Res Ther       Date:  2010-07-06       Impact factor: 2.250

9.  Dynamic regulation of host restriction factor expression over the course of HIV-1 infection in vivo.

Authors:  Rui André Saraiva Raposo; Mohamed Abdel-Mohsen; Xutao Deng; Frederick M Hecht; Christopher D Pilcher; Satish K Pillai; Douglas F Nixon
Journal:  J Virol       Date:  2014-07-16       Impact factor: 5.103

10.  Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control.

Authors:  April L Ferre; Peter W Hunt; J William Critchfield; Delandy H Young; Megan M Morris; Juan C Garcia; Richard B Pollard; Hal F Yee; Jeffrey N Martin; Steven G Deeks; Barbara L Shacklett
Journal:  Blood       Date:  2008-12-23       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.